This association was consistent across various treatment strategies (immunotherapy alone, in combination, or as part of immunochemotherapy), cancer types such as lung, sarcoma, and melanoma, and different spatial distributions of CD8+ T cells within the tumor microenvironment, including intra-tumoral, stromal, or at the invasive margin. Here, CD8A is linked to sarcoma.